<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725032</url>
  </required_header>
  <id_info>
    <org_study_id>HX-A-023(2020)</org_study_id>
    <nct_id>NCT04725032</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials</brief_title>
  <official_title>Comparison of the Effects of Total Intravenous Anesthesia and Balanced General Anesthesia on Flash Visual Evoked Potential Monitoring During Sellar Tumors Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraoperative flash visual evoked potentials (FVEPs) could monitor visual function during&#xD;
      neurosurgery. There are fewer reports comparing the effects of sevoflurane-propofol balanced&#xD;
      anesthesia and propofol-based total intravenous anesthesia under comparable bispectral index&#xD;
      (BIS) levels on the amplitude and latency of flash visual evoked potentials (FVEPs) for&#xD;
      sellar or parasellar tumors resection neurosurgeries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall incidence rate of sellar tumors is 10-20% of brain tumors. Most of the initial&#xD;
      symptoms of this tumor are visual or visual impairment. One of the primary complications of&#xD;
      these operations is visual impairment, which directly relates to the quality of patients'&#xD;
      life. Flash visual evoked potentials (FVEPs) is an important means of intraoperative visual&#xD;
      function evaluation under general anesthesia. Intraoperative visual function damage can be&#xD;
      avoided or reduced by observing the changing of FVEPs waves to guide the choice of surgical&#xD;
      path.&#xD;
&#xD;
      However, since the diversity of anesthetic drugs and methods, there is still a great&#xD;
      uncertainty impact on FVEPs, which will interfere with the interpretation and judgment of&#xD;
      surgeons and neuroelectrophysiological physicians respect to the changes of FVEPs amplitude&#xD;
      and latency, and further affect the operation decision-making. Therefore, it is urgent to&#xD;
      establish a perfect anesthesia method for intraoperative monitoring of FVEPs. Although total&#xD;
      intravenous anesthesia has been widely accepted for FVEPs monitoring, there are still some&#xD;
      limitations, such as the possibility of intraoperative body movement and cough due to the&#xD;
      restriction of muscle relaxant use under electrophysiological monitoring, as well as the&#xD;
      depression on FVEPs of high maintained dosage under total intravenous anesthesia. The purpose&#xD;
      of this study was to investigate the feasibility of FVEPs monitoring during endoscopic sellar&#xD;
      tumor resection under combined intravenous anesthesia compared with total intravenous&#xD;
      anesthesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N2 amplitudes of FVEPs</measure>
    <time_frame>90min after anesthesia induction</time_frame>
    <description>N145-P100 of FVEPs wave</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P100 latencies of FVEPs</measure>
    <time_frame>30, 60 and 90min after anesthesia induction</time_frame>
    <description>P100 latencies of FVEPs wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The visual acuity</measure>
    <time_frame>The day before surgery, and one day after operation.</time_frame>
    <description>The visual acuity before and after operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The visual field</measure>
    <time_frame>The day before surgery, and one day after operation.</time_frame>
    <description>The field of patients before and after operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N2 amplitudes of FVEPs</measure>
    <time_frame>30 and 60 after anesthesia induction</time_frame>
    <description>N145-P100 of FVEPs wave</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Brain Tumor Adult</condition>
  <arm_group>
    <arm_group_label>sevoflurane-propofol balanced anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol-based total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.</description>
    <arm_group_label>propofol-based total intravenous anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.</description>
    <arm_group_label>sevoflurane-propofol balanced anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years;&#xD;
&#xD;
          2. ASA I-III;&#xD;
&#xD;
          3. Elective sellar or parasellar tumors resection;&#xD;
&#xD;
          4. Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative visual acuity&lt;0.3;&#xD;
&#xD;
          2. BMI&gt;30kg/cm2;&#xD;
&#xD;
          3. Uncontrolled hypertension, diabetes or cardiac diseases;&#xD;
&#xD;
          4. Preoperative cognitive disorders;&#xD;
&#xD;
          5. Sedatives, alcohol or analgesic addiction history;&#xD;
&#xD;
          6. Allergy to drugs of this study or contact allergy to Silicone products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph. D</last_name>
    <phone>+861059976660</phone>
    <email>ruquan.han@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Enrolled subjects will be assigned a subject identification number</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

